Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins

Thrombosis and Haemostasis

Volumn 85, Issue 5, 2001, Pages 824-829

  Alban, S ^a   Gastpar, R ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Heparin; Low molecular weight heparin; Pharmacokinetics; Pharmacological profile; TFPI

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; HEPARIN; HEPARIN FRACTION; MONOEMBOLEX; TISSUE FACTOR PATHWAY INHIBITOR; VERY LATE ACTIVATION ANTIGEN 2;

ADULT; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFECT; HUMAN; HUMAN EXPERIMENT; MALE; MOLECULAR WEIGHT; NORMAL HUMAN; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 0035023991     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615755     Document Type: Article

References (29)

1. Tissue factor pathway inhibitor and the revised theory of coagulation
2. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI)
3. Synergism between full length TFPI and heparin: Evidence for TFPI as an important factor for the antithrombotic activity of heparin
4. Heparin/low molecular weight heparin and tissue factor pathway inhibitor
5. Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia
6. The present status of tissue factor pathway inhibitor
7. Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not posses anticoagulant function in tissue factor-induced coagulation in vitro
8. Human ryudocan from endothelium-like cells binds basic fibroblast growth factor, midlike, and tissue factor pathway inhibitor
9. Binding of tissue factor pathway inhibitor to cultured endothelial cells-influence of glycosaminoglycans
10. Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans
11. Antithrombin III affinity dependence on the anticoagulant, antiprotease, and tissue factor pathway inhibitor actions of heparins
12. The present status of tissue factor pathway inhibitor
13. Fucoidan, as heparin, induces tissue factor pathway inhibitor release from cultured human endothelial cells
14. Increase of total and especially free TFPI plasma concentration after i.v. application of anticoagulant β-1,3-glucan sulfates
15. The role of tissue factor parthway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin
16. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin
17. Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: Evidence for a difference in anithrombotic action
18. Minimalanforderungen zur Gewinnung von Citratplasma für hämostaseologische Analysen
19. In vitro influence of heparin on plasma total and free tissue factor pathway inhibitor (TFPI) as measured by ELISA
20. Pharmacokinetics, 2nd Edition
21. Pharmacokinetics of standard and low molecular weight heparin
22. Evidence that the C-terminus of tissue factor pathway inhibito (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins
23. Conjectures and refutations on the mode of action of heparins
24. Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins
25. The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man
26. Low-affinity heparin potentiates the action of high-affinity heparin oligosaccharides
27. Two receptor systems are involved in the plasma clearance of tissue factor pathway inhibitor in vivo